Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alector

- PMLiVE

GSK agrees on 10% equity stake in mRNA specialist CureVac

Equity investment totals £130m with an upfront payment of £104m

Biogen Idec building

Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3

Pivotal AHEAD 3-45 programme initiated this week

- PMLiVE

Biogen completes filing for highly-anticipated Alzheimer’s drug

FDA has 60 days to decide whether to accept filing for review

- PMLiVE

GSK signs deal with Medicago for COVID-19 vaccine

Collaboration will utilise GSK’s pandemic adjuvant platform

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

Alzheimer’s: the search for a cure

Will Biogen’s aducanumab re-energise the hunt for pharma’s white whale?

In Memory

Changing healthcare, one film at a time

Successfully marrying educational content with an entertaining format can help to truly maximise audience engagement

Bedrock Healthcare Communications

Great expectations: the urgent need for common purpose in Alzheimer’s disease

By Andrew Harrison

- PMLiVE

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Pivotal mid-stage trial results due later this month

- PMLiVE

GSK seeks EU approval for Trelegy in adult asthma patients

If approved would open up a large market for the triple therapy

- PMLiVE

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Gains rights to tau-targeting drug ST-501 as part of broader alliance

- PMLiVE

FDA accepts review to broaden GSK’s Zejula label

Seeks approval in advanced ‘all-comer’ ovarian cancer population

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links